Elizabeth Molsen

Content Validity—Establishing and Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product Evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 2—Assessing Respondent Understanding

Donald L. Patrick, Laurie B. Burke, Chad Gwaltney et al. · Value in Health · 2011 · 1.1K citations · Full text

Pharmacy, Quality Management, Good Clinical Practice +16

Content Validity—Establishing and Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product Evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 1—Eliciting Concepts for a New PRO Instrument

Donald L. Patrick, Laurie B. Burke, Chad Gwaltney et al. · Value in Health · 2011 · 1.1K citations · Full text

Pharmacy, Quality Management, Evidence-based Practice +16

Multinational Trials—Recommendations on the Translations Required, Approaches to Using the Same Language in Different Countries, and the Approaches to Support Pooling the Data: The ISPOR Patient-Reported Outcomes Translation and Linguistic Validation Good Research Practices Task Force Report

D Wild, Sonya Eremenco, I Mear et al. · Value in Health · 2008 · 322 citations · Full text

Humanities, Translation Studies, Translational Sciences +17

Clinical Outcome Assessments: Conceptual Foundation—Report of the ISPOR Clinical Outcomes Assessment – Emerging Good Practices for Outcomes Research Task Force

Marc K. Walton, John H. Powers, Jeremy Hobart et al. · Value in Health · 2015 · 318 citations · Full text

Pharmacy, Clinical Sciences, Outcomes Research +13

Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force

John H. Powers, Donald L. Patrick, Marc K. Walton et al. · Value in Health · 2017 · 180 citations · Full text

Pharmacy, Health Policy, Good Clinical Practice +13